Published • loading... • Updated
Researchers looking into whether GLP-1 drugs can help slow aging
Researchers are testing whether tirzepatide can slow biologic aging by 10% to 15%, building on early DNA-clock signals from prior studies.
- Researchers at the University of Texas Medical Branch in Galveston, Texas, are leading a clinical trial to determine if tirzepatide, the active ingredient in Zepbound, can slow biologic aging.
- Scientists are investigating whether GLP-1 medications may help slow the aging process, following past studies that are fueling interest in the class of drugs.
- The UTMB trial will follow adults between the ages of 55 and 70 who qualify for weight loss treatment, monitoring biological age markers, inflammation, cognitive function, strength, and mobility.
- After 32 weeks of semaglutide treatment, Dr. Michael Corley of UCSD reported that participants showed changes consistent with slower aging, calling the findings "a signal here that warranted future study."
- Experts emphasize that no scientific evidence currently supports healthy people taking GLP-1s for longevity, though Dr. Thomas Blackwell of UTMB hopes the research will show a 10 to 15% slowdown in biologic aging.
Insights by Ground AI
6 Articles
6 Articles
Coverage Details
Total News Sources6
Leaning Left2Leaning Right0Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
